Overexpression of LC3B correlates with malignant progression and aggressive behavior and predicts a poor clinical outcome in hepatocellular carcinoma, glioblastoma, and pancreatic ductal adenocarcinoma [33–35]. This evidence concerns the gene MAP1LC3B and glioblastoma.